Scientific research into immune active proteins proves the valuable nutritional benefits provided by these compounds. Unfortunately, there has never been a commercial source for these proteins, until now.
Only Tamarack Biotics’ products offer these levels of immune active proteins and other thermally sensitive compounds due to our non-thermal pathogen reduction process and low temperature drying systems.
Tamarack Biotics is currently conducting three clinical trials to demonstrate the nutritional benefits for:
Immunosenescence describes the condition whereby elderly people’s immune systems become less active and able to respond to a vaccine or illness. This double-blind, placebo-controlled study of 50 subjects investigates TruActive™’s effect on Pertussis vaccine response. The study is being conducted in California with UC Davis support. The study started in August 2016 and is expected to complete in early 2017.
TruActive™ is currently being tested on asthmatic mice to determine if a therapeutic effect is observed. This study is occurring in Switzerland and started in January 2017.
An extensive study of TruActive™’s ability to reduce allergy development in children is planned by researchers at the University Hospital Munich. This 3,000 post-weaning infant study will investigate asthma, atopic dermatitis and food allergy development along with respiratory infections over a 5-year period after 3 years of TruActive™ consumption. The double-blind, placebo-controlled study is expected to start in early 2018.